The Medicare Prescription Payment Plan (MPPP) is reshaping patient access by capping annual drug costs at $2,000. Early data from Konovo’s survey show rising confidence among providers and growing patient openness to branded therapies—though confusion, administrative barriers, and payer variability still limit full impact.
This report examines how the $2K Medicare cap is transforming cardio-metabolic care—boosting affordability, reshaping prescribing confidence, and driving stronger integration across specialties. You’ll also see where challenges remain, from patient confusion to payer hurdles, and how leaders like Lilly and Novo Nordisk are setting new standards in affordability communication.
Download the report now!
Download our ebook, “The Evolution of Market Research in Healthcare,” to discover the trends redefining the field and how Konovo is helping companies turn insight into action.
